|drug3896||intensive care unit admission ratio Wiki||1.00|
|D011655||Pulmonary Embolism NIH||0.26|
There is one clinical trial.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become pandemic. To date, no specific treatment has been proven to be effective. Promising results were obtained in China using Hyperimmune plasma from patients recovered from the disease.The investigators plan to treat critical Covid-19 patients with hyperimmune plasma.
Description: death from any causeMeasure: death Time: within 7 days
Description: days since intubationMeasure: time to extubation Time: within 7 days
Description: days from entry to exit from ICUMeasure: length of intensive care unit stay Time: within 7 days
Description: days since CPAP initiationMeasure: time to CPAP weaning Time: within 7 days
Description: naso-pharyngeal swab, sputum and BALMeasure: viral load Time: at days 1, 3 and 7
Description: neutralizing titleMeasure: immune response Time: at days 1, 3 and 7
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports